| Size | Price | |
|---|---|---|
| 100mg | ||
| 250mg | ||
| 500mg | ||
| Other Sizes |
| ln Vitro |
Ferruginol (0-160 μM) has potent antiproliferative actions on thyroid cancer cells, with a 24 hour half-life of 12 μM against the MDA-T32 cell line. It is less evident how harmful Ferruginol is to normal cells [1]. In MDA-T32 cells, ferruginol (0-24 μM; 24 hours) causes apoptotic cell death. Bcl-2 expression is downregulated and Bax expression is upregulated in a dose-dependent manner by ferruginol [1]. In MDA-T32 cells, ferruginol (0–24 μM; 24 hours) suppresses the PI3K/AKT and MAPK signaling pathways [1]. Additionally, in MDA-T32 cells, ferruginol (0–24 μM; 24 hours) induces ROS-mediated alterations in matrix metalloproteinases [1].
|
|---|---|
| ln Vivo |
Over the course of four weeks, ferruginol (20 mg/kg; oral; daily) exhibits cardioprotective effects that include reduced apoptosis and structural damage and improved heart function. By increasing PGC-1α expression and simultaneously promoting SIRT1, enhancing deacetylase SIRT1 deacetylation, and activating the expression of PGC-1α (MB and FAO), ferruginol promotes PGC-1α-mediated mitochondrial biogenesis and fatty acid oxidation, according to transcriptome and other results[3].
|
| Cell Assay |
Cell Viability Assay[1]
Cell Types: MDA-T32 cells Tested Concentrations: 0-160 μM Incubation Duration: 24 hrs (hours) Experimental Results: Exerted potent antiproliferative action against thyroid cancer cells. Apoptosis Analysis[1] Cell Types: MDA-T32 cells Tested Concentrations: 0 μM, 6 μM, 12 μM, and 24 μM Incubation Duration: 24 hrs (hours) Experimental Results: Induced apoptotic cell death of MDA-T32 cells Western Blot Analysis[1] Cell Types: MDA-T32 cells Tested Concentrations: 0 μM, 6 μM, 12 μM, and 24 μM Incubation Duration: 24 hrs (hours) Experimental Results: Blocked the MAPK and PI3K/AKT signaling pathway. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6 mice (20 g, 8-10 weeks old) with Doxorubicin (DOX)-induced cardiotoxicity (DIC)[3].
Doses: 20 mg/kg Route of Administration: Administered intragastrically (po); daily; for 4 weeks Experimental Results: Relieved Doxorubicin-induced cardiac structural and functional lesion. |
| References |
[1]. Guoqing Luo, et al. Ferruginol Diterpenoid Selectively Inhibits Human Thyroid Cancer Growth by Inducing Mitochondrial Dependent Apoptosis, Endogenous Reactive Oxygen Species (ROS) Production, Mitochondrial Membrane Potential Loss and Suppression of Mitogen-Activated Protein Kinase (MAPK) and PI3K/AKT Signaling Pathways. Med Sci Monit. 2019 Apr 21;25:2935-2942.
[2]. Weili Li, et al. Ferruginol Restores SIRT1-PGC-1α-Mediated Mitochondrial Biogenesis and Fatty Acid Oxidation for the Treatment of DOX-Induced Cardiotoxicity. Front Pharmacol. 2021 Nov 24;12:773834. [3]. Manabu Iwamoto, et al. Potential antitumor promoting diterpenoids from the stem bark of Thuja standishii. Planta Med. 2003 Jan;69(1):69-72. |
| Molecular Formula |
C20H30O
|
|---|---|
| Molecular Weight |
286.45
|
| CAS # |
514-62-5
|
| Appearance |
Typically exists as solids (or liquids in special cases) at room temperature
|
| SMILES |
CC(C)C1=C(C=C2C(=C1)CC[C@H]3C(C)(C)CCC[C@]23C)O
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4910 mL | 17.4551 mL | 34.9101 mL | |
| 5 mM | 0.6982 mL | 3.4910 mL | 6.9820 mL | |
| 10 mM | 0.3491 mL | 1.7455 mL | 3.4910 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
